Analysts Expect Foamix Pharmaceuticals (FOMX) Stock to Gain 398%; Rated Strong Buy


Foamix Pharmaceuticals (FOMX) stock is up more than 29% over the past week. FOMX stock is down -47.04% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. Stock Score Report, InvestorsObserver’s proprietary scoring system, gives FOMX stock a score of 76 out of a possible 100.

That score is chiefly influenced by a fundamental score of 87. In addition to the average rating from Wall Street analysts, FOMX stock has a mean target price of $15.60. This means analysts expect the stock to rise 398.40% over the next 12 months. FOMX’s score also includes a short-term technical score of 81. The long-term technical score for FOMX is 61.

Click Here to get the full Stock Score Report on Foamix Pharmaceuticals Ltd (FOMX).

What’s Happening with FOMX Stock Today

Foamix Pharmaceuticals Ltd (FOMX) stock has gained 16.79% while the S&P 500 has gained 1.25% as of 11:31 AM on Tuesday, Aug 13. FOMX has gained $0.45 from the previous closing price of $2.68 on volume of 989,319 shares. Over the past year the S&P 500 is higher by 3.44% while FOMX is down -47.04%. FOMX lost -$1.26 per share in the over the last 12 months.

Symbols: FOMX

You May Also Like